Patterson, Scott D.
https://orcid.org/0000-0002-9840-4964
Mayo Clinic
Gilead Sciences (United States)
Citations 2
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays
Hoofnagle, Andrew N. , Carr, Steven A. , Liu, Tao , Massoni, Sam A., Thomas, Stefani N. , Townsend, R. Reid , Zimmerman, Lisa J. , Boja, Emily S. , Chen, Jing , Crimmins, Daniel L., Davies, Sherri R. , Hiltke, Tara , Ketchum, Karen A. , Kinsinger, Christopher R. , Mesri, Mehdi , Meyer, Matthew R. , Qian, Weijun , Schoenherr, Regine M., Scott, Mitchell G., Shi, Tujin , Whiteley, Gordon , Wrobel, John A. , Wu, Chaochao, Ackermann, Brad, Barnidge, David R. , Bunk, David M. , Clarke, Nigel J. , Fishman, Jordan B., Grant, Russ P., Kushnir, Mark M. , Lowenthal, Mark S. , Neubert, Hendrik , Patterson, Scott D. , Rockwood, Alan L. , Rogers, John , Eyk, Jennifer E. Van , Wong, Steven, Zhang, Shucha, Chan, Daniel W. , Chen, Xian , Liebler, D.C. , Rodland, Karin , Rodriguez, Henry , Paulovich, Amanda G. , Whiteaker, Jeffrey R. , Kuhn, Eric W. , Gao, Yuqian , Aebersold, Ruedi , Grant, Russell P. , Kusebauch, Ulrike , Moritz, Robert L. , Singh, Ravinder J. , Ellis, Matthew J. , Smith, Richard , Zhang, Zhen , Zhang, Hui , Davies, S. J.
Clinical Chemistry | December 30, 2015 | Volume: 62 | Issue: 1 | Pages: 48-69
AbstractBACKGROUNDFor many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now beginning to deploy these work flows as well. For assays that use proteolysis to generate peptides for protein quantification and characterization, synthetic stable isotope–labeled internal standard peptides are of central importance. No general recommendations are currently available surrounding the use of peptides in protein mass spectrometric assays.CONTENTThe Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute has collaborated with clinical laboratorians, peptide manufacturers, metrologists, representatives of the pharmaceutical industry, and other professionals to develop a consensus set of recommendations for peptide procurement, characterization, storage, and handling, as well as approaches to the interpretation of the data generated by mass spectrometric protein assays. Additionally, the importance of carefully characterized reference materials—in particular, peptide standards for the improved concordance of amino acid analysis methods across the industry—is highlighted. The alignment of practices around the use of peptides and the transparency of sample preparation protocols should allow for the harmonization of peptide and protein quantification in research and clinical care.
Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy
Chen, Kexin , Yang, Da , Li, Xiangchun , Sun, Baocun , Song, Fengju , Cao, Wenfeng , Gao, Zhibo, Li, Haixin , Liang, Han , Zhao, Yanrui, Li, Miao , Buckner, Jan C. , Patterson, Scott D. , Reinhard, Christoph , Bhathena, Anahita, Joshi, Deepa, Wang, Yi Michael, Raghavakaimal, Sreekumar, Lü, Xin , Chang, Han , Ba, Sujuan, Luo, Longhai, Cavenee, Webster K. , Zhang, Wei , Hao, Xishan , Chen, Kexin , Buckner, Jan, Sun, Baocun , Brat, Daniel J. , Zheng, Hong , Ye, Xiang , Mischel, Paul S. , Croce, Carlo Maria , Li, Hui , Pan, Yang
Proceedings of the National Academy of Sciences | January 13, 2015 | Volume: 112 | Issue: 4 | Pages: 1107-1112
Significance We have identified a lethal subtype of gastric cancer (GC) that is characterized by high levels of clonal heterogeneity and TP53 (tumor protein P53) mutation. We have also uncovered key novel mutations in the targetable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair and identified BRCA2 (breast cancer 2, early onset) mutations as new genetic markers to predict better survival for GC. Our study represents a novel approach for GC personalized medicine and identified novel clinical actionable therapies for GC therapy.